Abstract
Type 2 diabetes (T2D) is a national health priority. Its rising prevalence isaccompanied by a high burden of diabetes-related complications, many ofwhich are preventable. Numerous glucose-lowering medications have beendeveloped in recent years with growing evidence relating to their efficacy and safety. These advances haveincreased the complexity of prescribing decisions inT2D. This review provides clinicians with relevant evidence and practical advice concerning glucagon-like peptide-1 receptor agonists (GLP1-RAs) in T2D. The Royal Australian College of General Practitioners recommends GLP1-RAs as an option for second-line therapy in T2D. GLP1-RAs contribute to weight loss and glycated haemoglobin reduction. GLP1-RAs also reduce incidence of cardiovascular events in selected populations, and available evidence suggests renoprotective effects. Common adverse effects include gastrointestinal symptoms, especially in the weeks following treatment initiation. GLP1-RAs should be considered for people with T2D at high cardiovascular risk or where weight loss is a priority.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
